RxDoctor Payments Data

Lauren Harbin

Family · Savannah, TNNPI 1164873360

Payments from drug & device makers

$490in general payments, 2019–2025

Across 22 payments — averaging $22.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$113
  • Novo Nordisk$109
  • AbbVie$62
  • Axsome Therapeutics, Inc.$52
  • Lundbeck LLC$45
  • Otsuka America Pharmaceutical, Inc.$25
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$44591%
  • Education$459%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$490 in reported general payments places this provider in the 50th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$45,128
Medicare patients
108
Services billed
2,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$91,214
MounjaroTirzepatide72$75,089
VraylarCariprazine Hcl34$48,475
XifaxanRifaximin12$39,412
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$35,512
XareltoRivaroxaban43$35,453
RexultiBrexpiprazole22$34,458
EliquisApixaban45$31,614
LinzessLinaclotide47$30,915
TrulicityDulaglutide20$21,839
FarxigaDapagliflozin Propanediol27$19,356
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$15,447
LyricaPregabalin14$12,599
TrintellixVortioxetine Hydrobromide21$10,954
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen362$10,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$113$96,92892 claims
Novo NordiskOzempic$109$91,21485 claims
AbbVieVraylar, Linzess$62$79,39081 claims
PfizerEliquis, Lyrica, Premarin$20$46,48471 claims
AstraZenecaFarxiga, Breztri Aerosphere$19$34,80347 claims
Otsuka America Pharmaceutical, Inc.Rexulti$25$34,45822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,706 family providers in Tennessee.

Other family in Savannah

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →